Katherine R. Pelz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katherine R. Pelz has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Rosalie C. Sears
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA
64 shared publications - Colin J. Daniel
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon
62 shared publications - Jennifer Eng
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR
40 shared publications - Jonathan Robert Brody
Department of Surgery, Oregon Health & Science University
40 shared publications - Kevin MacPherson-Hawthorne
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR
40 shared publications - Koei Chin
Oregon Health & Science University 3 Knight Cancer Institute Portland, Oregon
39 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Tumor ELAVL1 (HuR) expression correlates with patient outcome and T cell infiltration in PDAC.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Tumor ELAVL1 (HuR) expression correlates with patient outcome and T cell infiltration in PDAC.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Antibody information for mIHC staining
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Antibody information for mIHC staining
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Tumor ELAVL1 (HuR) expression correlates with patient outcome and T cell infiltration in PDAC.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Tumor ELAVL1 (HuR) expression correlates with patient outcome and T cell infiltration in PDAC.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
HuR restricts the function and infiltration CD8 T cells in PDAC
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
HuR restricts the function and infiltration CD8 T cells in PDAC
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
HuR limits T cell infiltration and activation, promoting an immunosuppressive and myeloid-driven TME landscape
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
HuR limits T cell infiltration and activation, promoting an immunosuppressive and myeloid-driven TME landscape
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Flow cytometry gating strategies.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Flow cytometry gating strategies.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Metabolic flux analysis from single-cell RNA sequencing data
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Metabolic flux analysis from single-cell RNA sequencing data
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Gating strategies for lineage assignment in mIHC
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Gating strategies for lineage assignment in mIHC
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Cell marker for annotation for single-cell RNA sequencing.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
Cell marker for annotation for single-cell RNA sequencing.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
HuR stabilizes anabolic transcripts and metabolic pathways.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma
HuR stabilizes anabolic transcripts and metabolic pathways.